Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Uptravi
Pharma
FDA signs off on Merck’s potential blockbuster Winrevair for PAH
With the FDA’s approval of Winrevair to treat pulmonary arterial hypertension, Merck is set to launch the first disease-modifying treatment for PAH.
Kevin Dunleavy
Mar 26, 2024 5:11pm
FDA approves Johnson & Johnson's combo pill Opsynvi for PAH
Mar 25, 2024 11:05am
In PAH patients, J&J's combo pill Opsynvi increases blood flow
Mar 6, 2023 9:37am
Janssen rounds out final live talk of 2022 for PH nurses
Dec 7, 2022 10:31am
J&J hosts educational talks online for PA nurses
May 20, 2022 8:35am
FDA approves intravenous version of J&J's Uptravi
Aug 3, 2021 9:50am
